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Retroviruses have evolved effective strategies to evade the host immune response, such as high variability
and latent infection. In addition, primate lentiviruses, such as HIV-1, have acquired several ‘‘accessory’’
genes that antagonize antiviral host restriction factors and facilitate viral immune evasion, thereby allowing
continuous and efficient viral replication despite apparently strong innate and acquired immune responses.
Here, I summarize some of our current knowledge on the acquisition and function of the viral vif, vpr, vpu, and
nef genes, with a particular focus on the evolution and specific properties of pandemic HIV-1 strains that may
contribute to their efficient spread and high virulence.Introduction
Since their introduction into the human population by a single
transmission event from a chimpanzee infected with a simian
immunodefiency virus (SIVcpz) to a human early in the last
century (Korber et al., 2000; Worobey et al., 2008), pandemic
HIV-1 group M (major) strains have infected about 60 million
people. Despite this rapid spread, the efficiency of sexual virus
transmission that accounts for more than 80% of all HIV-1 infec-
tions is usually surprisingly poor (1 per 1000 sexual contacts)
and most often results from a single ‘‘founder’’ virus (Keele
et al., 2008). It is not well understoodwhymost genital exposures
to HIV-1 do not lead to a spreading infection. Possible explana-
tions are protective effects of the mucosal layer, limited target
cell availability, or elimination of HIV-1 by innate immunity factors
(reviewed in Haase, 2010). Once an infection is established,
however, HIV-1 spreads very rapidly and eliminates most
memory CCR5+CD4+ helper T cells in lymphoid tissues within
a few weeks (reviewed in Brenchley and Douek, 2008). Although
apparently vigorous innate and virus-specific adaptive immune
responses are induced, HIV-1 is capable of replicating continu-
ously and efficiently in the infected host. One reason for this
lack of immunological control is that the virus has evolved
multiple properties to evade or counteract the host defense
mechanisms (Table 1). Some features helping HIV-1 to evade
the immune system are (1) Hiding/latency: the retroviral genome
is integrated into that of its host cell. Many HIV-1-infected cells
are minimally activated or dormant and cannot be recognized
and eliminated by the immune system as long as they do not
express viral antigens. Some latently infected cells survive for
many years, thus precluding virus eradication. (2) Variation/
escape: the reverse transcriptase makes about one error per
10,000 nucleotides, and HIV-1 is highly recombinogenic.
Because billions of viruses are produced each day and the viral
generation time is short, the potential for variation is enormous.
Thus, HIV-1 evolves in fast motion, resulting in the rapid selection
of viral quasi-species that have a growth advantage because
they are not recognized by the antibodies or cytotoxic T lympho-
cytes (CTLs) in the respective host. (3) Camouflage: most
antibodies react very poorly with the native oligomeric envelope
proteins present on HIV-1 particles. Reasons for this are thatabout half of the mass of the Env glycoprotein consists of
variable carbohydrates and that conserved functional domains
are masked by variable loops and only transiently exposed
during viral entry (reviewed in Johnson and Desrosiers, 2002).
Thus, broadly neutralizing antibodies are extremely rare. (4)
Cell tropism: helper CD4+ T cells sense viral infections by
T cell receptor (TCR)-mediated interactions with foreign peptides
on MHC and release cytokines and chemokines to promote
antibody and CTL responses. However, activated CD4+ T cells
are also the ideal viral targets. Usually, the virus infects and
eliminates most of them during acute infection and leaves the
infected host with little CD4 help. Only a small minority of virally
infected individuals maintain strong HIV-specific CD4 prolifera-
tive capacity and can achieve long-term immunological control
of viral replication. (5) Cell-to-cell spread: HIV-1 can spread
directly from infected to uninfected cells via virological syn-
apses. This may protect the virus sterically and kinetically from
immune effector mechanisms (reviewed in Sattentau, 2008).
Another reason for the lack of immunological control of HIV-1 is
that theadaptive immune response takes time todevelopandcan
only become effective in response to an infection that is already
ongoing. Thus, by the time CTLs emerge, the virus has already
spread efficiently in the host, damaged the immune system,
and established latent reservoirs. The innate immune response
occursmore rapidlybut is also largelydependenton the response
to ongoing viral replication, e.g., virus-triggered signaling, to
induce the interferon (IFN) response. However, in addition to
conventional innate and acquired immune responses, humans
and other mammals have also evolved specific antiviral factors.
These ‘‘intrinsic immunity’’ or ‘‘host restriction’’ factors are
constitutively expressed in some cell types and are induced by
interferons as part of the innate immune response in others.
They have the advantage that they do not have to ‘‘learn’’ to
combat virusesbut arealreadyactive at the first virus-cell interac-
tion (reviewed in Malim and Emerman, 2008; Neil and Bieniasz,
2009). Three major classes of retroviral restriction factors have
been identified. APOBEC3G (apolipoprotein B mRNA-editing
enzyme, catalytic polypeptide-like 3G) was the first host gene
identified as an inhibitor of HIV-1 infection (Sheehy et al., 2002).
APOBEC3G is a cytidine deaminase that suppresses reverseCell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc. 55
Table 1. Host Defenses and Mechanisms of Primate Lentiviral Evasion or Antagonism
Immune
Response Host Defense Antiviral Effect
Viral Evasion or
Antagonistic Mechanism
Viral Factor(s) or
Properties
Innate NK cells lysis of infected cells selective downmodulation
of HLA-A and -B,
but not HLA-C and -E
Nef
Intrinsic ABOBEC 3G lethal hypermutations polyubiquitination
and degradation
Vif
TRIM5a untimely uncoating variation in capsid high variability
tetherin blocks virion release sequestration from the site
of virion budding
Vpu, Nef, Env
Acquired cytotoxic CD8+ T cells lysis of infected cells,
inhibitory cytokines
MHC-I downmodulation, escape
mutations, latent infection
Nef, high variability
CD4+ helper T cells helper function to
promote antibody
and CTL responses
destruction by infection
or bystander apoptosis;
downmodulation of CD4,
CD3, CD28, and CXCR4
Nef, Vpu, viral cytopathicity
B cells, antibodies neutralization antigenic variation,
glycosylation, shielding of
functional epitopes, inhibition
of IgG2, and IgA switching
high variability, N-linked
glycosylation sites,
Env structure, Nef
antigen-presenting cells viral antigen presentation,
helper T cell activation
upmodulation of Ii surface
expression
Nef
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genome, which are detrimental to viral replication. TRIM5a
(tripartite motif 5-a) proteins were originally discovered as
important determinants of the resistance of monkey cells to
HIV-1 infection (Stremlau et al., 2004). TRIM5a binds incoming
viral capsids in the cytoplasm and seems to mediate rapid
uncoating. Themost recently identified restriction factor, tetherin
(BST-2, CD317, or HM1.24), inhibits viral release by ‘‘tethering’’
mature virions to the cell surface (Neil et al., 2008; Van Damme
et al., 2008). However, it is obvious from the high levels of viremia
during acute infection that this front line of antiviral defense fails to
protect humans against the spreadof HIV-1. The reason for this is
that HIV-1 and other primate lentiviruses have evolved specific
‘‘tools’’ to antagonize these host restriction factors. These viral
factorswerenamed ‘‘accessory’’ because theyarenot absolutely
required for viral replication in cell lines. However, they allow
HIV-1 to replicate continuously at high levels in the presence of
strong innate, intrinsic, and adaptive virus-specific immune
responses and thus play important roles for viral persistence,
pathogenesis, and transmission in vivo. The mechanisms under-
lying the function of the HIV-1 accessory Vif, Vpr, Vpu, and Nef
proteins have been the topic of several recent in-depth reviews
(Arie¨n and Verhasselt, 2008; Chiu and Greene, 2009; Kirchhoff
et al., 2008; Malim and Emerman, 2008; Malim, 2009; Neil and
Bieniasz, 2009; Planelles and Benichou, 2009). Here, I describe
the acquisition of these factors, summarize (some of) their func-
tions, highlight specific features of pandemic HIV-1 M strains,
andmention future questions and challenges. Themain objective
is to give an impression of themultitudes of strategies evolved by
primate lentiviruses to evade or counteract the host defenses.
Acquisition of Accessory Genes by HIV-1
HIV-1 belongs to the genus of lentiviruses. These viruses are
characterized by their ability to infect nondividing cells and to56 Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc.cause diseases with long incubation periods. Lentiviruses have
been divided into five groups, each restricted to a single mam-
malian family, i.e., ovines-caprines, bovines, felines, equines,
and primates. Until recently, only exogenous lentiviruses were
known, and their evolutionary analysis suggested that they
emerged relatively recently. However, though the extremely
high rates of evolution of infectious primate lentiviruses facilitate
the reconstruction of recent evolutionary events, such as the
emergence of HIV-1, they preclude the reliable analysis of their
distant evolutionary history and origin. The recent discovery
and analysis of distinct endogenous lentiviruses has provided
important information on the origin and evolution of current lenti-
viruses and indicates a considerably more ancient origin than
previously anticipated (Gifford et al., 2008; Katzourakis et al.,
2007; Keckesova et al., 2009). For example, the presence of an
endogenous lentivirus in a lemur from Madagascar (named
gray mouse lemur prosimian immunodeficiency virus, pSIVgml)
suggests that lentiviruses have been infecting primates for
more than 10 million years (Gifford et al., 2008).
In addition to the gag, pol, and env genes, which encode struc-
tural and enzymatic proteins and are present in the genomes of
all retroviruses, the most primitive known lentivirus (i.e., rabbit
endogenous lentivirus type K, RELIK) contains just the tat and
rev genes encoding essential regulatory proteins (Figure 1).
The discovery of a RELIK ortholog in the genome of European
hares revealed that these lagomorph lentiviruses are at least
12 million years old (Keckesova et al., 2009). In comparison,
the genomes of present day primate lentiviruses, found in about
40 African nonhuman primate species (reviewed in Hahn et al.,
2000; Pandrea et al., 2008), contain at least three additional
genes (vif, vpr, and nef). Vif is also present in the genomes of
the ovine-caprine, bovine, and feline (but not in the equine)
groups of lentiviruses and was thus acquired early during lentivi-
ral evolution. In contrast, vpr and nef genes are characteristic for
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Figure 1. Genomic Organization of Lentiviruses
The organization of the consensus endogenous RELIK and pSIVgml proviral
genomes is shown in comparison to that of other infectious lentiviruses.
RELIK, rabbit endogenous lentivirus type K; FIV, feline immunodeficiency
virus; OMVV, ovine maedi-visna virus; pSIVgml, gray mouse lemur prosimian
immunodeficiency virus. Question marks indicate the possible presence of
short, spliced Rev and Tat exons.
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that evaded the host genome several million years ago contains
a dUTPase, which is otherwise only found in nonprimate lentivi-
ruses (Gifford et al., 2008). In addition to vif, vpr, and nef, SIVs
infecting the Papionini tribe of monkeys (mangabeys, drills,
and mandrills) and HIV-2 contain a vpx gene. Vpx may have
arisen from a duplication of the vpr open reading frame (Tristem
et al., 1990) or by the acquisition of a heterologous vpr gene
(Sharp et al., 1996). Finally, another gene (vpu) was most likely
acquired by a common ancestor of SIVs nowadays found in
Cercopithecus monkeys (Bailes et al., 2003). To our current
knowledge, this vpu containing SIV was transmitted to chimpan-
zees and formed a hybrid with the ancestor of an SIV found in
red-capped mangabeys (Cercocebus torquatus) (Bailes et al.,
2003). Chimpanzees prey on these monkeys, and their ranges
in west and central Africa overlap. Most likely, one chimpanzee
became coinfected by both simian viruses. They recombined,
and the vpu-containing hybrid virus (SIVcpz) then spread in
chimpanzees and was later transmitted to humans and gorillas
to become HIV-1 and SIVgor. Thus, Vpu distinguishes HIV-1
and its SIV counterparts in chimpanzees, gorillas, and some
Cercopithecus monkeys from most other primate lentiviruses
that do not encode a homolog to Vpu.Accessory HIV-1 Proteins Antagonizing Host Restriction
Factors
Compared to the most primitive retroviruses, HIV-1 is equipped
with six additional genes. Two of them encode essential regula-
tory proteins (Tat and Rev) and four small accessory factors
(Vif, Vpr, Vpu, and Nef) that are dispensable for viral replication
in some cell types. Accumulating evidence suggests that the
main function of three of the latter, i.e., Vif, Vpu, and (most likely)
Vpr, is to counteract intracellular proteins that humans and other
mammals have evolved primarily or exclusively as a defense
against viral pathogens (reviewed in Malim and Emerman,
2008). The necessity of such antiviral factors and the enormity
of encounters with invading retroviruses over millions of years
are evident from the fact that about 8% of our genome consists
of the defective remnants of once infectious retroviruses
(reviewed in Bannert and Kurth, 2004). This is a larger proportion
of our genetic material than that encoding proteins. Thus, retro-
viruses have not only left their imprints, but have also driven our
evolution and shaped our genetic repertoire. Similarly to highly
active antiretroviral therapy (HAART), antiviral ‘‘host restriction’’
factors interfere with different stages of the viral life cycle:
APOBEC3G induces lethal hypermutations of the retroviral
genome; TRIM5a proteins restrict the incoming retroviral capsid;
and tetherin inhibits the release of viral particles (reviewed in
Huthoff and Towers, 2008; Malim and Emerman, 2008; Neil
and Bieniasz, 2009) (Figure 2). Its high variability allows HIV-1
to evade the adaptive immune response. In comparison, it is
more difficult for the virus to avoid factors targeting viral compo-
nents in a less-specific manner because it cannot easily become
resistant by escape mutations. TRIM5a proteins inhibit viruses
with limited homology and thus seem to target viral capsids
with a relatively relaxed specificity. However, escape by capsid
mutations is clearly possible, as retroviruses from a given
species are not restricted by the TRIM5a variants found in the
same species (reviewed in Song, 2009). Of interest, binding of
the HIV-1 capsid protein to cyclophilin A increases its suscepti-
bility to simian TRIM5a and may thus reduce its potential for
cross-species transmission (Keckesova et al., 2006). Incorpora-
tion of APOBEC3G proteins into budding virions and inhibition of
virus release by tetherin are both relatively unspecific processes
(reviewed in Bieniasz, 2004; Malim and Emerman, 2008). Thus,
HIV-1 is unable to avoid them by escapemutations but has taken
the highly demanding step of acquiring new tools to antagonize
these intrinsic immunity factors. Of note, the functional charac-
terization of the viral antagonists was frequently instrumental in
identifying the host restriction factors. As outlined in a recent
review (Malim and Emerman, 2008), Vif, Vpu, and Vpr all seem
to target antiviral factors for ubiquitin-dependent proteasomal
degradation to render the intracellular environment more condu-
cive to viral replication. In comparison, the multifunctional HIV-1
Nef protein interacts with numerous cellular factors and evolved
to facilitate viral immune evasion from adaptive immune
responses and to directly promote viral spread.
Virion infectivity factor (Vif) is a basic protein of 23 kDa that
is essential for viral replication in primary T cells and in vivo
(reviewed in Malim, 2009; Chiu and Greene, 2009). Its cellular
target, APOBEC3G, was initially discovered by theMalim labora-
tory by comparing the mRNA expression profiles of cells that do
or do not support efficient replication of vif-defective HIV-1Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc. 57
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Figure 2. Host Restriction Factors and Their Viral Antagonists
As schematically indicated, TRIM5a (T5a) interacts with incoming HIV-1 capsids andmay induce accelerated uncoating by proteasomal degradation. Vif binds to
a cullin 5-based ubiquitin ligase complex and to APOBEC3G (3G) to induce the degradation of the restriction factor in proteasomes. Without Vif, APOBEC3G is
incorporated into budding virions and causes lethal G-to-A hypermutations of the retroviral genome in the next round of infection. Tetherin inhibits the release of
mature viral particles from the cell surface and is antagonized by the Vpu protein. The exact mechanism remains to be defined but most likely involves direct
interaction and b-TrCP2-dependent degradation of tetherin, leading to its sequestration from budding virions.
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Review(Sheehy et al., 2002). In the absence of Vif, APOBEC3G is incor-
porated into HIV-1 virions (Sheehy et al., 2003; Stopak et al.,
2003; Mariani et al., 2003), inhibits viral DNA synthesis during
reverse transcription (Holmes et al., 2007; Miyagi et al., 2007;
Bishop et al., 2008), and catalyzes deamination of cytidine to
uridine during negative-strand DNA synthesis (Conticello et al.,
2005). These changes lead to the degradation of the viral DNA
and/or become fixed as guanosin-to-adenosin transitions in
the proviral sequences (known as G-to-A hypermutations).
APOBEC3G is particularly effective in inactivating the virus
because it preferentially targets GG dinucleotides, thereby
changing TGG (W) to TAA (stop) codons. Such mutations seem
to be responsible for the inactivation of some ancient retroviral
sequences (Esnault et al., 2005; Jern et al., 2007). Vif serves as
an adaptor molecule to link a cullin 5-based E3 ubiquitin ligase
complex to APOBEC3G and induces its polyubiquitination and
subsequent proteasomal degradation, thereby preventing its
packaging into budding virions (Figure 2). It has been reported
that ABOBEC3G exists in an enzymatically active low-molecular
mass form that restricts HIV-1 in quiescent T cells but is recruited
into high-molecular mass RNA-protein complexes upon T cell
activation (Chiu et al., 2005). Of interest, the latter also contain
Alu/hY retroelements and may reduce their transposition (re-
viewed in Chiu and Greene, 2009). Some recent studies,
however, did not confirm the role of low-molecular mass
ABOBEC3G complexes in the HIV-1-restrictive phenotype of
quiescent T cells (Kamata et al., 2009; Santoni de Sio and Trono,
2009). Thus, further investigation is required to fully understand
the regulation and antiviral properties of APOBEC3G. Of note,
APOBEC3G is only one of seven related cytidine deaminases58 Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc.found in humans. Vif also mediates the degradation of
APOBEC3F, which is another potent inhibitor of HIV-1 (Mehle
et al., 2004; Yu et al., 2003). Furthermore, the expression of trun-
cated or misfolded viral proteins due to APOBEC3G editing
enhances the recognition of HIV-1-infected T cells by CTLs
and thus links the innate and adaptive immune response (Casar-
telli et al., 2010a). Low levels of APOBEC3G-mediated muta-
tions, however, may actually be beneficial for the virus because
they may help HIV-1 to diversify rapidly and to escape from
adaptive immunity (Simon et al., 2005; Sadler et al., 2010).
HIV-1 viral protein R (Vpr) is a virion-associated factor of about
14 kDa. Multiple activities of Vpr, including activation of proviral
transcription, cell-cycle arrest in the G2 phase, induction of cell
death, and enhancement of the fidelity of reverse transcription,
have been reported (reviewed in Malim and Emerman, 2008;
Planelles and Benichou, 2009). Of note, an intact vpr gene is
not required for efficient viral replication and progression to
AIDS in the SIVmac/macaque model (Gibbs et al., 1995),
although its conservation between all primate lentiviruses
suggests a relevant role in natural SIV and recent HIV infections.
The ability of Vpr to cause a G2 cell-cycle arrest is preserved
between HIV and SIV (Fletcher et al., 1996). Several recent
studies suggest that it involves the interaction of Vpr with the
cullin 4A-DDB1 complex via DCAF-1 (initially named VprBP)
(reviewed inMalim and Emerman, 2008; Planelles and Benichou,
2009). It is currently unclear whether Vpr increases the activity of
the cullin 4A-DDB1-DCAF-1 complex for its normal substrates or
allows it to recruit a novel one for ubiquitination and degradation.
In either case, the characterization of this substrate will be highly
important for our understanding of Vpr function. It may also help
Cell Host & Microbe
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increases HIV-1 transcription (Goh et al., 1998) or whether it is
just a side effect of the destruction of a factor playing a dual
role in cell-cycle progression and host-mediated viral restriction.
Of note, HIV-1 Vpr also facilitates infection of macrophages
(Balliet et al., 1994; Connor et al., 1995). In the HIV-2/SIVsmm
lineage that also contains a vpx gene, the two major functions
of Vpr are segregated: Vpr induces cell-cycle arrest, and Vpx
facilitates infection of macrophages (albeit with much higher
efficiency than HIV-1 Vpr) (Goujon et al., 2007; Sharova et al.,
2008). Importantly, Vpx also binds DCAF-1 to interact with the
cullin 4A-DDB1 complex, and this interaction seems critical for
its ability to promote macrophage infection (Le Rouzic et al.,
2007; Srivastava et al., 2008). Thus, it is tempting to speculate
that Vpx (and Vpr) may target an as yet unknown restriction
factor expressed in macrophages for polyubiquitination and
degradation.
HIV-1 viral protein U (Vpu) is a 16 kDa integral membrane
protein produced together with Env during the late stage of the
viral life cycle. Vpu has two main functions. First, it interacts
with newly synthesized CD4 in the endoplasmatic reticulum
and recruits a ubiquitin ligase complex to its cytoplasmic tail to
mediate polyubiquitinylation and proteasomal degradation
(Bour et al., 1995; Willey et al., 1992). CD4 is the primary receptor
of all primate lentiviruses. Thus, its degradation may facilitate
virus release, avert superinfection, and enhance the incorpora-
tion of functional Env proteins into progeny virions by preventing
the formation of gp120/CD4 complexes in virally infected cells.
Second, Vpu is required for efficient viral particle release in
some cell types but only after type I interferon treatment in others
(Strebel et al., 1989; Go¨ttlinger et al., 1993).Microarray screening
for membrane-associated proteins constitutively expressed in
cells in which Vpu is required for efficient virion release and
induced by IFN-a treatment in those in which it is dispensable
allowed the identification of BST-2 as the antiviral factor antago-
nized by Vpu (Neil et al., 2008). An independent study (Van
Damme et al., 2008) also identified this long-sought ‘‘tethering’’
factor by following up on a previous report showing that BST-2
is downmodulated from the plasma membrane by the Kaposi’s
sarcoma associated herpes virus (KSHV) protein K5, a viral
ubiquitin ligase, and by Vpu (Bartee et al., 2006). BST-2, or
‘‘tetherin’’ as it is now commonly called, is a type II single-pass
transmembrane protein with a cytoplasmic N-terminal region,
followed by a transmembrane (TM) domain, a coiled-coil extra-
cellular domain, and a C-terminal glycophosphatidylinositol
(GPI) anchor (Kupzig et al., 2003). It also contains three cysteine
residuesmediating homodimerization. Since its discovery by the
Bieniasz and Guatelli labs, there has been a flurry of papers on
tetherin and its viral antagonists, and this has been the topic of
several recent reviews (Malim and Emerman, 2008; Neil and
Bieniasz, 2009; Ruiz et al., 2010; Sauter et al., 2010). In brief,
tetherin dimers seem to directly tether nascent virions to the
surface of the producer cells with onemembrane anchor sticking
in the virion and the other in the cell membrane (Figure 2). In
agreement with this straightforward mechanism, the cyto-
plasmic tail and the GPI anchor are both critical for its antiviral
activity (Neil et al., 2008). Furthermore, an artificial ‘‘tetherin’’
composed of entirely different sequences but with comparable
topology inhibits virus release (Perez-Caballero et al., 2009).Recent data suggest that its conformational flexibility may help
tetherin to maintain its anchoring in both the cellular and viral
membranes during virion budding (Hinz et al., 2010). Usually,
tetherin is not expressed at high levels in primary CD4+ T cells.
However, its expression is strongly induced by type I interferons
(Neil et al., 2007). Vpu interacts with the TM domain of tetherin in
a highly specific manner and targets the restriction factor to the
trans-Golgi network or to early endosomes for proteasomal and/
or lysosomal degradation by a b-TrCP-dependent mechanism
(Douglas et al., 2009; Goffinet et al., 2009; Gupta et al., 2009;
Mangeat et al., 2009; McNatt et al., 2009). Vpu reduces the levels
of tetherin expression at the cell surface (Van Damme et al.,
2008;Mitchell et al., 2009; Douglas et al., 2009). However, down-
modulation and/or degradation of tetherin may not always be
required for the capability of Vpu to promote virion release
(Dube´ et al., 2010; Goffinet et al., 2010; Miyagi et al., 2009; Neil
et al., 2008). Thus, though it is clear that Vpu keeps tetherin
away from the sites of virion budding, the exact mechanism of
tetherin antagonism needs further study.
The finding that HIV-1 developed an effective tetherin antago-
nist clearly supports a relevant role of this restriction factor
in vivo. However, HIV-1 O strains can cause AIDS, although their
Vpu and Nef proteins are poor tetherin antagonists (Sauter et al.,
2009). Early data suggested that Vpu may not be required
for effective cell-to-cell spread (Gummuluru et al., 2000). Thus,
ineffective tetherin antagonism could just shift the spread of
HIV-1 to cell-to-cell transmission. However, a recent study
suggests that tetherin also restricts cell-to-cell spread of the
virus, albeit with limited efficiency (Casartelli et al., 2010b).
Furthermore, HIV-1 replication is hypersensitive to IFN-a (which
induces tetherin) in the absence of Vpu (Neil et al., 2007), and
intact vpu genes are required for effective replication in ex
vivo-infected human lymphoid tissues (Schindler et al., 2010).
Thus, the importance of tetherin antagonism for viral replication
both in vitro and in vivo remains to be clarified.
All-Rounder Nef: Manipulation and Evasion
of Adaptive Immunity
The negative factor (Nef) of HIV-1 is a myristoylated protein of
about 27 kDa associated with cytoplasmic membranes and
abundantly expressed early during the viral life cycle. Its name
is misleading because intact nef genes are critical for the main-
tenance of high virus loads and accelerate disease progression
in HIV-1-infected human individuals and in SIVmac-infected rhe-
susmacaques (Kestler et al., 1991; Deacon et al., 1995; Kirchhoff
et al., 1995). Nef performs a striking number of activities and
induces complex changes in cellular trafficking, gene and
receptor surface expression, antigen presentation, and signal
transduction (reviewed in Arie¨n and Verhasselt, 2008; Kirchhoff
et al., 2008). Furthermore, Nef may also affect the survival and
function of bystander cells (Lenassi et al., 2010) and deregulate
the communication between T cells and antigen-presenting cells
(Arhel et al., 2009; Thoulouze et al., 2006). Thus, most likely,
multiple Nef activities cooperate to delay the elimination of
HIV-1-infected cells by the immune system to turn them into
more effective producers of fully infectious virions and to render
the cellular environment more conducive for viral spread.
In HIV-1-infected T cells, Nef downmodulates CD4, MHC-I,
and (less efficiently) CD28 and CXCR4 (CXCL12) from theCell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc. 59
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Figure 3. Schematic Presentation of Selected Nef Functions
Nef downmodulates HLA molecules, CD4, CD28, CXCR4, and CD3 from the surface of infected CD4+ T cells by recruiting them to the endocytic machinery via
interactions with adaptor protein 2 (AP2) complexes or by rerouting them to endosomes. These Nef functions reduce CTL lysis, suppress cell migration, facilitate
virus release, and modulate signal transduction by the immunological synapse. Furthermore, Nef interacts with cellular kinases and induces downstream
signaling events to modulate T cell activation; to induce rearrangements of the actin skeleton; to activate NF-AT, NF-kB, and AP-1; and to induce the efficient
transcription of the viral LTR promoter, as well as of cellular genes, including those encoding inflammatory cytokines, activation markers, and death receptors.
Nef also directly enhances the infectivity of progeny virions. As indicated by green boxes, SIVagm and SIVsmm Nef alleles are more effective than those of HIV-1
in modulating CD28 and CXCR4 and, in addition, also downregulate CD3. Thus, in contrast to HIV-1 Nefs, they prevent the formation of the immune synapse and
not just deregulate it. As indicated by the orange box, cells expressing HIV-1 Nefs express higher levels of death receptors and inflammatory cytokines than those
expressing SIVsmm or SIVagm Nef proteins. Modified from Arhel and Kirchhoff, 2009.
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or by rerouting them to lysosomes for degradation (reviewed in
Roeth and Collins, 2006; Arhel and Kirchhoff, 2009). These Nef
functions protect virally infected T cells against CTL lysis, reduce
their migration in response to the chemokine SDF-1 (CXCL12),
prevent superinfection, and may facilitate the release of fully
infectious virions (Figure 3). Of note, Nef selectively downmodu-
lates HLA-A and –B, but not HLA-C or –E, alleles from the cell60 Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc.surface (Cohen et al., 1999) to balance escape from CTL lysis
with protection from attack by natural killer cells. Furthermore,
Nef interacts with various cellular kinases and modulates signal
transduction pathways to manipulate the responsiveness of
virally infected T cells to TCR-mediated stimulation. As a conse-
quence, the HIV-1 Nef protein promotes the induction of cellular
transcription factors, such as NF-AT, NF-kB, and AP-1, that
elevate the transcription of the viral LTR promoter and thus viral
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Reviewreplication (Fenard et al., 2005; Fortin et al., 2004; Manninen
et al., 2001). Nef also affects MHC-II antigen presentation by
efficient upmodulation of the Invariant chain (Ii or CD74) at the
cell surface (Stumptner-Cuvelette et al., 2001). Ii usually caps
the MHC-II peptide-binding site during its transport to endoso-
mal compartments to prevent premature peptide loading.
Upmodulation of immature MHC-II-Ii complexes at the cell
surface perturbs MHC-II-restricted antigen presentation (Roche
et al., 1992). Thus, this Nef function may contribute to the
impaired helper T cell responses observed in AIDS patients.
Although Nef is commonly considered an early viral gene
product, it also acts during the late stage of the virus life cycle.
For example, Nef enhances the infectivity of progeny virions by
a poorly defined mechanism that involves the interaction of Nef
with the GTPase Dynamin-2, an essential regulator of clathrin-
mediated endocytosis (Pizzato et al., 2007). Furthermore, as dis-
cussed below, some SIVs use their Nef proteins to antagonize
tetherin (Jia et al., 2009; Sauter et al., 2009; Zhang et al., 2009).
Accumulating evidence suggests that Nefmay not onlymanip-
ulate HIV-1-infected host cells, but also cause significant
changes in its cellular environment. For example, Nefmay induce
the secretion of factors from HIV-1-infected macrophages that
attract T cells and render them more susceptible to HIV-1 infec-
tion (Swingler et al., 1999, 2003). Furthermore, it has been
proposed that the HIV-1 Nef protein itself is secreted and may
trigger apoptosis in bystander CD4+ T cells (James et al.,
2004; Lenassi et al., 2010). Finally, it has been reported that
Nef induces the formation of long-range actin-propelled con-
duits in infected macrophages to mediate its own transfer to
neighboring B cells (Xu et al., 2009). B cells containing Nef
showed impaired IgG2 and IgA class switching, suggesting
that HIV-1 may exploit Nef to manipulate the antibody response
and to evade humoral immunity (Qiao et al., 2006).
The relevance of most Nef activities for viral replication and
pathogenesis in vivo is far from clear and has been discussed
in greater depth in recent reviews (Foster and Garcia, 2008;
Kirchhoff et al., 2008). It has become clear that different Nef
functions require distinct elements and are often genetically
separable. In some cases, this allowed the specific elimination
of individual Nef activities. For example, the analysis of highly
selective SIVmac239 mutants containing changes in the
C-terminal domain of Nef demonstrated that MHC-I downmodu-
lation is associated with a strong selective advantage and
reduces CD8+ T cell responses in infected rhesus macaques
(Mu¨nch et al., 2001; Swigut et al., 2004). More often, however,
mutations in Nef have pleiotropic effects, and this is a major
obstacle for conclusive studies on the relevance of specific
Nef functions in vivo. Altogether, the results obtained in the
SIV/macaque model show that mutations in Nef that disrupt
some but not all of its activities usually result in a phenotype
intermediate between wild-type and nef-deleted SIVmac infec-
tion (reviewed in Kirchhoff et al., 2008). This implies that both
the Nef functions that are maintained, as well as those that are
disrupted, play some role for viral replication in vivo. The
emerging picture suggests that HIV-1 and SIV evolved Nef as a
multifunctional tool to manipulate the key cell types of the
acquired immune system (helper CD4+ T cells, CTLs, B cells,
and APCs) and to interfere with the various mechanisms (such
as antigen presentation, cellular migration, signal transduction,apoptosis, and cytokine secretion) critical for the immunological
control of the virus.
Adaptations Preceding the Emergence
of Pandemic HIV-1 Strains
Genes encoding host restriction factors, such as TRIM5a,
APOBEC3G, and tetherin, evolve unusually fast (Sawyer et al.,
2004, 2007; McNatt et al., 2009). This positive selection for
diversification is most likely driven by the need to antagonize
new emerging pathogens or to escape viral antagonists over
millions of years of virus-host coevolution. As a consequence,
TRIM5a, APOBEC3G, and tetherin all show a high degree of
sequence divergence and constitute barriers to zoonotic viral
transmissions because the viral antagonists often act in a
species-specific manner. Nonetheless, primate lentiviruses
have crossed species barriers on many occasions, and HIV-1
is the product of successive zoonotic transmission and recombi-
nation events (Figure 4). As mentioned above, SIVcpz most likely
arose from a recombination between ancestors of SIVs presently
infecting red-capped mangabeys and Cercopithecus monkeys
(Bailes et al., 2003). Subsequently, SIVcpz was transmitted
from chimpanzees to gorillas and to humans to give rise to
SIVgor and HIV-1. Recent studies provide the first insights on
how these primate lentiviruses managed to jump from one
species to another (Gaddis et al., 2004; Kratovac et al., 2008;
Sauter et al., 2009; Schindler et al., 2006).
TRIM5a has been first identified as a major barrier to HIV-1
replication in rhesus macaque cells (Stremlau et al., 2004).
Human and chimpanzee TRIM5a proteins, however, seem to
be unable to restrict different primate lentiviruses, including
SIVgsn and SIVcpz (Kratovac et al., 2008). The inability of chim-
panzee TRIM5a to restrict SIVs found in small monkeys most
likely facilitated coinfection by different lentiviruses and thus
the generation of the chimeric virus that adapted to chimpan-
zees. Species-specific differences in the susceptibility of
ABOBEC proteins may also play a role in cross-species viral
transmission. Indeed, the anti-APOBEC activity of various SIV
Vif proteins in transfected H9 cells seems to correlate with the
capability of these viruses to infect humans (Gaddis et al.,
2004). However, the capability of these SIVs to antagonize
ABOBEC did not correlate with their replicative capacity in
human cells, and some SIVs were partly resistant to human
APOBEC proteins irrespectively of Vif function. Thus, the role
of ABOBEC in primate lentiviral replication is complex, and it
remains elusive whether ABOBEC constituted a barrier for the
transmission of SIVs from small monkeys to chimpanzees. This
was clearly not the case for the later transmission of the virus
from chimpanzees to humans because the SIVcpz Vif is fully
capable of antagonizing human ABOBEC proteins (Gaddis
et al., 2004).
Tetherin most likely posed a significant hurdle to the cross-
species transmissions that preceded the emergence of HIV-1.
The chimeric virus that gave rise to SIVcpz contained the vpu
gene of the precursor of SIVgsn/mus/mon and the nef gene of
the progenitor of SIVrcm (Schindler et al., 2006). Most likely,
the ancestor of SIVrcm used Nef (because it does not encode
Vpu) and that of the SIVgsn/mus/mon lineage used Vpu (because
all descendants do) to antagonize tetherin. Thus, the hybrid virus
was equipped with two potential tetherin antagonists. However,Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc. 61
Figure 4. Tetherin-Driven Evolution of Vpu and Nef Function and the Emergence of HIV-1
SIVcpz represents a recombinant of the precursors of viruses nowadays found in red-capped mangabeys and Cercopithecusmonkeys and was transmitted to
humans and gorillas. Vpuwas first acquired by a common precursor of SIVgsn/mus/mon and then transferred frommonkeys to apes and to humans by zoonotic
primate lentiviral transmissions. The events that led to the emergence of pandemic HIV-1 group M strains are indicated by thick lines. Nef-mediated tetherin
antagonism is indicated by blue and Vpu-mediated tetherin antagonism by red lines, respectively. +, active; (+), poorly active; , inactive; ?, unknown; n.a.,
not applicable because these viruses do not have a vpu gene. Adapted from Sauter et al., 2009.
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species transmission because Vpus and/or Nef proteins of
SIVs infecting smaller monkeys are poor antagonists of chim-
panzee tetherin (Sauter et al., 2009). Subsequently, Nef, and
not Vpu, evolved to become an effective tetherin antagonist
in SIVcpz-infected chimpanzees, most likely because the cyto-
plasmic domain targeted by Nef is somewhat less divergent
between the chimpanzee and monkey tetherin sequences than
the transmembrane domain targeted by Vpu (reviewed in Sauter
et al., 2010). In contrast, Vpu lost its anti-tetherin activity during
adaptation to chimpanzees but maintained its capability to
degrade the CD4 receptor. After transmission of SIVcpz from
chimpanzees to gorillas, it was easy for the virus to adapt to
this new host because the CPZ and GOR tetherin sequences
differ only by two amino acid changes in the cytoplasmic domain
targeted by Nef (Sauter et al., 2009). This was different after the
species jump of SIVs from chimpanzees and gorillas to humans.
The human tetherin variant contains a deletion in the cytoplasmic
region, which most likely evolved to escape an ancient viral
antagonist and renders human tetherin resistant to Nef (Jia
et al., 2009; Sauter et al., 2009; Zhang et al., 2009). Pandemic
HIV-1 M strains mastered this hurdle perfectly by switching
from Nef to Vpu to regain efficient anti-tetherin activity in the
new human host (Sauter et al., 2009). In contrast, the Vpu
proteins of nonpandemic HIV-1 O strains remained poor tetherin
antagonists, and those of the rare HIV-1 group N strains gained
some anti-tetherin activity but lost their capability to degrade
CD4. Thus, this deletion poses a significant, but not insurmount-
able, barrier for viral transmissions from chimpanzees to hu-62 Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc.mans. The result that only pandemic HIV-1 M strains evolved
fully functional Vpu proteins suggests a possible role in sexual
transmission. Thus, it will be interesting to determine whether
Vpu-mediated tetherin antagonism and/or CD4 degradation
may affect the shedding of infectious virions into the genital
fluids.
The direct simian precursor of HIV-2, SIVsmm from sooty
mangabeys, does not contain a vpu gene and counteracts
tetherin by Nef (Jia et al., 2009; Zhang et al., 2009). Recently, it
has been shown that HIV-2 instead uses its Env protein to antag-
onize human tetherin (Le Tortorec and Neil, 2009). Thus, the
deletion in human tetherin obviously forced both human immu-
nodeficiency viruses to switch from Nef to a different tetherin
antagonist, i.e., Vpu or Env. This illustrates the enormous
plasticity by which lentiviruses can adapt to new hosts. Of
note, only two (groups A and B) of at least seven cross-species
transmissions of SIVsmm from sooty mangabeys to humans
resulted in significant spread in the human population (Butler
et al., 2007). Thus far, anti-tetherin activity has only been demon-
strated for the Env protein of the group A HIV-2 ROD strain, but
not for the remaining groups of HIV-2 (Le Tortorec and Neil,
2009). To assess a possible role of tetherin in the spread of
HIV-2, it will be interesting to determine whether also the HIV-2
group B Env proteins, but not those of group C-H HIV-2 strains,
show anti-tetherin activity.
Possible Effects of Vpu on Nef Function
As outlined above, the functions of Vpu and Nef overlap
because both reduce the levels of CD4 at the cell surface and
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may have facilitated evolutionary changes in Nef function.
The great majority of primate lentiviral Nef proteins remove
TCR-CD3 from the cell surface, whereas vpu-containing viruses,
such asHIV-1, fail to perform this function (Schindler et al., 2006).
Furthermore, HIV-2 and most SIV Nefs also downmodulate
CD28 much more efficiently than those of HIV-1. As a conse-
quence, the great majority of primate lentiviral Nefs block the
responsiveness of virally infected T cells to stimulation (Figure 4).
In contrast, the effect of HIV-1 Nef on T cell activation is some-
what controversial. Some studies showed that HIV-1-infected
CD4+ T cells are hyperresponsive to stimulation (Fortin et al.,
2004; Schindler et al., 2006), whereas others reported inhibitory
effects (Thoulouze et al., 2006). In either case, it is evident that
Nef proteins derived from nonpathogenic SIVs that downmodu-
late CD3 interfere with T cell activation and the formation and
function of the immunological synapse between T cells and
APCs much more severely than HIV-1 Nefs (Arhel et al., 2009).
It remains elusive why the acquisition of a vpu gene reduced
the selective pressure for the suppression of T cell activation. I
have proposed that viruses expressing Vpu could perhaps afford
to lose the ability to block T cell activation and thus to cause
higher levels of immune activation because they are better
equipped to counteract the host restriction factors induced by
high levels of inflammatory IFN-a than viruses lacking a vpu
gene (Kirchhoff, 2009). This still seems plausible, although recent
results show that this issue is more complex than anticipated
because many SIVs lacking Vpu use their Nef proteins to antag-
onize tetherin (Jia et al., 2009; Sauter et al., 2009; Zhang et al.,
2009). Furthermore, SIVcpz and SIVgor Nefs did not regain the
‘‘lost’’ CD3 downmodulation function, although their Vpu
proteins are poor tetherin antagonists (Sauter et al., 2009).
However, it may be much easier for the virus to lose than to
regain specific activities. Furthermore, HIV-1 and SIVgsn/mus/
mon Vpus may be more effective tetherin antagonists than
SIVsmm and SIVagm Nef proteins (Jia et al., 2009; Lim and
Emerman, 2009; Sauter et al., 2009; Zhang et al., 2009). It seems
logical that SIVagm and SIVsmm need less-effective tetherin
antagonists than HIV-1 because they only transiently induce
interferon production in vivo (Bosinger et al., 2009; Jacquelin
et al., 2009). Thus, the expression of tetherin during chronic
infection should be lower than in pathogenic HIV-1 infection.
Furthermore, it seems reasonable that a more specialized teth-
erin antagonist like Vpu may evolve to become more effective
than an ‘‘all-rounder’’ protein like Nef. However, many results
on Vpu and Nef function come with the caveat that both acces-
sory proteins were expressed in trans by expression constructs.
Different expression levels and the time frame that they are
produced in the viral life cycle may have an important impact
on the anti-tetherin activity of Vpu and Nef. Thus, more studies
in virally infected primary cells are needed to draw definitive
conclusions about the efficiency by which different primate
lentiviruses antagonize tetherin.
Whatever the reason is for why vpu-containing primate
lentiviruses lost their capability to block T cell activation, it may
have relevant implications for their pathogenicity. It is well known
that some SIVs, such as SIVagm and SIVsmm, do not cause
disease in their natural simian hosts despite high levels of viral
replication (Paiardini et al., 2009; Sodora et al., 2009). Forsome reason, these natural hosts of SIV are able to avoid the
chronic, generalized immune system activation that seems to
drive disease progression in HIV-infected individuals. It has
been proposed that an inborn defect in the ability of plasmacy-
toid dendritic cells to produce IFN-a in response to viral infection
is responsible for the lack of aberrant chronic immune activation
in natural SIV infection (Mandl et al., 2008). Subsequent studies
have shown, however, that SIV infection triggers rapid and
strong IFN-a responses in both African green monkeys and
sooty mangabeys (Bosinger et al., 2009; Jacquelin et al.,
2009). However, in contrast to pathogenic HIV-1 and SIVmac
infections, this response was transient. Thus, the lack of a sus-
tained type I IFN response during chronic natural SIV infection
is not due to a genetic inability to produce IFN-a but, rather,
occurs because this response can rapidly be controlled. It is
evident that both viral and host factors contribute to the develop-
ment of the different levels of immune activation after the acute
phase of pathogenic and nonpathogenic infection (Paiardini
et al., 2009; Sodora et al., 2009). It is conceivable that a virus
that blocks T cell activation may make it easier for the infected
host to develop lower levels of immune activation than a virus
that renders infected T cells hyperresponsive to stimulation.
These viral properties may not only affect the fate of virally
infected cells, but also the survival and function of uninfected
bystander cells because hyperactivated HIV-1-infected T cells
express death receptors and secrete inflammatory cytokines.
Downmodulation of CD3 and (to a lesser extent) CD28 would
be expected to impair the function of helper CD4+ T cells and
thus mainly the initiation and strength of the acquired immune
response, but not the induction of IFN by HIV-1 during acute
infection. This may potentially explain why different levels of
immune activation in pathogenic and nonpathogenic infection
develop after acute infection with the rise of the acquired
immune response. In support of a protective role in vivo, ineffi-
cient downmodulation of TCR-CD3 by Nef correlates with loss
of CD4+ T cells in natural SIVsmm (Schindler et al., 2008)
and increased levels of immune activation in HIV-2-infected
individuals (Feldmann et al., 2009). However, Nef-mediated
downmodulation of TCR-CD3 to suppress T cell activation and
programmed death is only one of several mechanisms contrib-
uting to nonpathogenic infection, and host factors also play an
important role (reviewed in Pandrea et al., 2008; Paiardini
et al., 2009; Sodora et al., 2009). This is most evident from the
fact that efficient CD3 downmodulation is insufficient to prevent
progression to AIDS in SIV-infected macaques and in HIV-2-in-
fected individuals (Kestler et al., 1991; Feldmann et al., 2009).
Nonetheless, accumulating evidence suggests that the acquisi-
tion of a vpu gene may have allowed the viral lineage that gave
rise to HIV-1 to evolve toward greater pathogenicity by removing
the selective pressure for a protective Nef function that prevents
damaging levels of immune activation (reviewed in Kirchhoff,
2009). The findings that HIV-1 is more pathogenic than HIV-2
and that SIVcpz causes AIDS in its natural chimpanzee host
(Keele et al., 2009) are in agreement with this hypothesis. Obvi-
ously, AIDS is a consequence of imperfect virus-host adaptation
because a perfectly adapted virus does not ‘‘commit suicide’’
and reduces its chance for transmission by killing its hosts.
However, it is conceivable that a virus that causes higher levels
of cellular activation may outgrow a less virulent form, and theCell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc. 63
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within less than a hundred years after zoonotic transmission is
daunting evidence that the time frame from virus infection to
death is sufficient for effective viral spread.
Conclusions and Perspectives
Current data show that the ongoing ‘‘arms race’’ between
lentiviruses and their hosts started long ago, is inextricably
intertwined, and involves a considerably more sophisticated
arsenal of ‘‘weapons’’ than previously anticipated. Basically,
humans and other mammals had already developed a kind of
combination therapy long before HAART because they evolved
specific antiviral factors that interfere with different steps of the
viral life cycle, such as reverse transcription, uncoating, and
virion release. In some aspects, these cellular antiviral factors
are even superior to antiretroviral drugs because they have
broad antiviral activity and often HIV-1 cannot just avoid them
by escape mutations. Instead, HIV-1 and other primate lentivi-
ruses have acquired specific tools to antagonize these ancient
antiviral defense mechanisms. Furthermore, they evade adap-
tive immunity by their high variability and by a striking combina-
tion of Nef activities. As a consequence, primate lentiviruses are
capable of replicating efficiently and continuously in the pres-
ence of apparently strong antiviral immune responses. In fact,
recent data show that the expression of IFN-stimulated genes
encoding intrinsic antiretroviral defense factors in HIV-1-infected
individuals correlates with increasing viral loads (Rotger et al.,
2010), suggesting that they have become indicators rather
than suppressors of HIV-1 replication. Of note, the high viral
loads damage the immune system and cause AIDS mainly in
poorly adapted recent or experimental hosts, such as humans
or macaques. Most primate lentiviruses seem to coexist in a
relatively benign relationship with their natural primate hosts
because they can avoid damaging high levels of immune activa-
tion during chronic infection. It is possible that the acquisition of
Vpu facilitated the emergence of primate lentiviruses, such as
HIV-1, that cause higher levels of immune activation and damage
because they are unable to block T cell activation. Furthermore,
the evolution of a fully functional Vpu protein may have facilitated
the spread of pandemic HIV-1 group M strains.
Although exciting progress has been made, we are only just
beginning to understand the complex interactions between
lentiviruses and their hosts. For example, it is currently largely
unclear whether known host restriction factors contribute to
the control of HIV-1 in vivo and how many as-yet-unknown
antiviral factors remain to be identified. A better understanding
of the virus-host interactions seems important for many reasons.
For example, comparative studies of pathogenic and nonpatho-
genic primate lentiviral infections may teach us how the high
levels of damaging immune activation can be avoided. This
seems particularly relevant because immune activation seems
to be a problem even under HAART and may cause a premature
aging of the immune system. Studying the viral immune evasion
mechanisms may teach us how better immunological control of
HIV-1 can be achieved because it is evident that viruses evolve
to manipulate exactly those immune functions that would be
otherwise most relevant for their control. It will also be interesting
to assess whether the inhibition of the viral antagonists or the
specific induction of the natural cellular defense mechanisms64 Cell Host & Microbe 8, July 22, 2010 ª2010 Elsevier Inc.to overpower them represent useful strategies to improve antire-
troviral therapy. It may even be possible to develop improved
artificial restriction factors with broad-based antiviral activity
that are resistant to the viral antagonists (Perez-Caballero
et al., 2009). Such studies are challenging but may be very
rewarding because it will be difficult for HIV-1 to become
resistant against host restriction factors. Furthermore, host
restriction factors do not only inhibit HIV-1 and may be effective
against a variety of viral pathogens.ACKNOWLEDGMENTS
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